Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg
Executive Summary
Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg
You may also be interested in...
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Ortho-McNeil Adds Axert To Pain Portfolio; Pfizer Left With One Triptan
Ortho-McNeil will enter the triptan migraine class by taking over Pharmacia's marketing rights to Axert